Arcadia Biosciences (NASDAQ:RKDA) Announces Quarterly Earnings Results

Arcadia Biosciences (NASDAQ:RKDA) released its quarterly earnings results on Thursday. The basic materials company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.32), Zacks reports. Arcadia Biosciences had a negative net margin of 48.15% and a positive return on equity of 34.16%. The firm had revenue of $0.90 million for the quarter, compared to the consensus estimate of $1.40 million.

Arcadia Biosciences Trading Down 3.3%

NASDAQ RKDA opened at $1.47 on Friday. The company’s 50 day moving average is $1.89 and its two-hundred day moving average is $2.92. Arcadia Biosciences has a 12 month low of $1.46 and a 12 month high of $6.71. The stock has a market cap of $2.54 million, a price-to-earnings ratio of -0.85 and a beta of 0.57.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcadia Biosciences in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, Arcadia Biosciences presently has an average rating of “Sell”.

About Arcadia Biosciences

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.